Frisiosol 1,5 % glucose, 1,25 mmol/l calcium solution for pritoneal dialysis Búlgaría - búlgarska - Изпълнителна агенция по лекарствата

frisiosol 1,5 % glucose, 1,25 mmol/l calcium solution for pritoneal dialysis

fresenius medical care deutschland gmbh - Глюкоза - 1,5 % glucose, 1,25 mmol/l calcium solution for pritoneal dialysis

Frisiosol 4,25 % glucose, 1,25 mmol/l calcium solution for pritoneal dialysis Búlgaría - búlgarska - Изпълнителна агенция по лекарствата

frisiosol 4,25 % glucose, 1,25 mmol/l calcium solution for pritoneal dialysis

fresenius medical care deutschland gmbh - Глюкоза - 4,25 % glucose, 1,25 mmol/l calcium solution for pritoneal dialysis

Frisiosol 2,3 % glucose, 1,25 mmol/l calcuim solution for peritoneal dialysis Búlgaría - búlgarska - Изпълнителна агенция по лекарствата

frisiosol 2,3 % glucose, 1,25 mmol/l calcuim solution for peritoneal dialysis

fresenius medical care deutschland gmbh - Глюкоза - 2,3 % glucose, 1,25 mmol/l calcuim solution for peritoneal dialysis

Lipanthyl Supra 160 mg film - coated tablets Búlgaría - búlgarska - Изпълнителна агенция по лекарствата

lipanthyl supra 160 mg film - coated tablets

mylan medical sas - Фенофибрат - 160 mg film - coated tablets

Lipanthyl 200 M 200 mg capsules, hard Búlgaría - búlgarska - Изпълнителна агенция по лекарствата

lipanthyl 200 m 200 mg capsules, hard

mylan medical sas - Фенофибрат - 200 mg capsules, hard

Driptane 5 mg tablets Búlgaría - búlgarska - Изпълнителна агенция по лекарствата

driptane 5 mg tablets

mylan medical sas - Оксибутинин - 5 mg tablets

Солу-Медрол 250 mg прах и разтворител за инжекционен разтвор Búlgaría - búlgarska - Изпълнителна агенция по лекарствата

Солу-Медрол 250 mg прах и разтворител за инжекционен разтвор

pfizer enterprises sarl - Метилпреднизолон -

Libtayo Evrópusambandið - búlgarska - EMA (European Medicines Agency)

libtayo

regeneron ireland designated activity company (dac) - cemiplimab - Карцином, сквамозна клетка - Антинеопластични средства - cutaneous squamous cell carcinomalibtayo as monotherapy is indicated for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma (mcscc or lacscc) who are not candidates for curative surgery or curative radiation. basal cell carcinomalibtayo as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic basal cell carcinoma (labcc or mbcc) who have progressed on or are intolerant to a hedgehog pathway inhibitor (hhi). non-small cell lung cancerlibtayo as monotherapy is indicated for the first-line treatment of adult patients with non-small cell lung cancer (nsclc) expressing pd-l1 (in ≥ 50% tumour cells), with no egfr, alk or ros1 aberrations, who have:locally advanced nsclc who are not candidates for definitive chemoradiation, ormetastatic nsclc. libtayo in combination with platinum‐based chemotherapy is indicated for the first‐line treatment of adult patients with nsclc expressing pd-l1 (in ≥ 1% of tumour cells), with no egfr, alk or ros1 aberrations, who have:locally advanced nsclc who are not candidates for definitive chemoradiation, ormetastatic nsclc. cervical cancerlibtayo as monotherapy is indicated for the treatment of adult patients with recurrent or metastatic cervical cancer and disease progression on or after platinum-based chemotherapy.

DepoCyte Evrópusambandið - búlgarska - EMA (European Medicines Agency)

depocyte

pacira limited - цитарабин - Менингеални неоплазми - Антинеопластични средства - Интратекално лечение на лимфоматозен менингит. При повечето пациенти подобно лечение ще бъде част от симптоматичното палиатиране на заболяването.

Kimmtrak Evrópusambandið - búlgarska - EMA (European Medicines Agency)

kimmtrak

immunocore ireland limited - tebentafusp - uveal neoplasms - Антинеопластични средства - kimmtrak is indicated as monotherapy for the treatment of human leukocyte antigen (hla)-a*02:01-positive adult patients with unresectable or metastatic uveal melanoma.